EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis

Jesús Fortún iD, Elia Gómez-García de la Pedrosa, Alberto Martínez-Lorca, Patricia Paredes iD, Pilar Martín-Dávila, Alicia Gómez-López, María José Buitrago iD, Javier López-Jiménez iD, Francesca Gioia, Rosa Escudero iD, Maria Elena Alvarez-Alvarez, Cruz Soriano iD und 4 weitere

Journal of Fungi · 01.03.2024 · 10 (3) · 191

DOI: 10.3390/jof10030191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 01.03.2024. Verfasst von Jesús Fortún und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Universitario "Ramon y Cajal", Avda Colmenar Km 9,1, 28034 Madrid, Spain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Health's 'Fondo de Investigaciones Sanitarias' (Health Research Fund;, ‘Fondo de Investigaciones Sanitarias’ (Health Research Fund) of the Spanish Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although nebulized liposomal amphotericin B (NLAB) is being used in invasive pulmonary aspergillosis (IPA) prophylaxis, no clinical trial has shown its efficacy as a therapeutic strategy. NAIFI is the inaugural randomized, controlled clinical trial designed to examine the safety and effectiveness of NLAB (dosage: 25 mg in 6 mL, three times per week for 6 weeks) against a placebo, in the auxiliary treatment of IPA. Throughout the three-year clinical trial, thirteen patients (six NLAB, seven placebo) were included, with 61% being onco-hematological with less than 100 neutrophils/μL. There were no significant differences noted in their pre- and post-nebulization results of forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and oxygen saturation between the groups. Neither bronchospasm nor serum amphotericin B levels were reported in any patients given NLAB. 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET-TC) was carried out at the baseline and after 6 weeks. A notable decrease in median SUV (standardized uptake value) was observed in NLAB patients after 6 weeks (−3.6 vs. −0.95, p: 0.039, one tail). Furthermore, a reduction in serum substance galactomannan and beta-D-Glucan was identified within NLAB recipients. NLAB is well tolerated and safe for patients with IPA. Encouraging indirect efficacy data have been derived from image monitoring or biomarkers. However, further studies involving more patients are necessary.

Schlagwörter

Stichwörter der Autor:innen

18F-fluorodeoxyglucose positron emission tomographyinvasive pulmonary aspergillosisnebulized liposomal amphotericin B

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Universitario "Ramon y Cajal", Avda Colmenar Km 9,1, 28034 Madrid, Spain.
  • Instituto de Investigación Sanitaria Hospital "Ramón y Cajal" (IRYCIS), 28034 Madrid, Spain.
  • Department of Medicine, Universidad Alcalá, 28801 Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de 5 Salud Carlos III, 28029 Madrid, Spain.
  • Department of Microbiology, Hospital Universitario "Ramon y Cajal", 28034 Madrid, Spain.
  • Department of Nuclear Medicine, Hospital Universitario "Ramon y Cajal", 28034 Madrid, Spain.

ORCID-Profile: Jesús Fortún, Patricia Paredes, María José Buitrago, Javier López-Jiménez, Rosa Escudero, Cruz Soriano, Noelia Vicente, Santiago Moreno

Förderung

  • Spanish Ministry of Health's 'Fondo de Investigaciones Sanitarias' (Health Research Fund;
  • ‘Fondo de Investigaciones Sanitarias’ (Health Research Fund) of the Spanish Ministry of Health

Zitieren

APA

Fortún, J., Gómez-García de la Pedrosa, E., Martínez-Lorca, A., Paredes, P., Martín-Dávila, P., Gómez-López, A., Buitrago, M. J., López-Jiménez, J., Gioia, F., Escudero, R., Alvarez-Alvarez, M. E., Soriano, C., Moreno-García, J., San Miguel, D., Vicente, N., & Moreno, S. (2024). A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis. Journal of Fungi, 10(3), 191. https://doi.org/10.3390/jof10030191

Vancouver

Fortún J, Gómez-García de la Pedrosa E, Martínez-Lorca A, Paredes P, Martín-Dávila P, Gómez-López A, et al. A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis. Journal of Fungi. 2024;10(3):191. doi:10.3390/jof10030191

BibTeX
@article{Fortn2024,
  author = {Fortún, Jesús and Gómez-García de la Pedrosa, Elia and Martínez-Lorca, Alberto and Paredes, Patricia and Martín-Dávila, Pilar and Gómez-López, Alicia and Buitrago, María José and López-Jiménez, Javier and Gioia, Francesca and Escudero, Rosa and Alvarez-Alvarez, Maria Elena and Soriano, Cruz and Moreno-García, Javier and San Miguel, Diana and Vicente, Noelia and Moreno, Santiago},
  title = {A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis},
  journal = {Journal of Fungi},
  year = {2024},
  volume = {10},
  number = {3},
  pages = {191},
  doi = {10.3390/jof10030191}
}
Kostenlos starten →